Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 6/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644704 | 0.84 | KDM4E (0.39) | SPRKDM4EGRM4L3MBTL1TDP1 | |
| SCHEMBL24469660 | 0.84 | KDM4E (0.39) | SPRKDM4EGRM4L3MBTL1TDP1 | |
| SCHEMBL30983274 | 0.76 | ACHE (0.44) | SPRKDM4EPOLBALDH1A1RAB9A | |
| SCHEMBL21818641 | 0.76 | KDM4E (0.38) | KDM4EASPHKDM8KDM5AKDM4C | |
| SCHEMBL31133332 | 0.76 | KDM4E (0.38) | KDM4EASPHKDM8KDM5AKDM4C | |
| SCHEMBL8647924 | 0.76 | ACHE (0.48) | KDM4EPOLBALDH1A1RAB9AMAPT | |
| SCHEMBL251512 | 0.75 | CYP1A2 (0.57) | KDM4EALDH1A1CYP3A4MAPTALOX15 | |
| Hydrochloric Acid SCHEMBL21877747 | 0.75 | GRM4 (0.34) | SPRGRM4TDP1 | |
| SCHEMBL973641 | 0.73 | CYP1A2 (0.55) | KDM4EALDH1A1ALOX15TSHR | |
| SCHEMBL21182079 | 0.73 | SMN1; SMN2 (0.39) | SPRKDM5AKDM4CKDM5BGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010516-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-02 | — | — | EP | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| EP-0540526-A1 | QUINUCLIDINE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001688-A1 | QUINUCLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | SPR 1270/4885KDM4E 2489/4885ASPH 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.